Table 1 PREVENT-AD participant characteristics

From: Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults

PREVENT-AD sample characteristics

Sample size

104

Age in years

67.4 (4.9)

Female, % (n)

71.1 (74)

Years of education

15 (3.1)

APOE ε4 carriers, % (n)

40.3 (42)

Global Aβ SUVR index

1.29 (0.31)

Entorhinal cortex tau SUVR

1.08 (0.13)

Temporal meta-ROI tau SUVR

1.12 (0.10)

MoCA score (baseline)

28.1 (1.5)

MMSE score (MEG–PET visit)

28.8 (1.2)

  1. Summary of relevant metrics from the PRe-symptomatic EValuation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD) participants included in this study. The table shows the key demographics, as well as the group average (and s.d.) global Aβ and temporal tau PET SUVR, baseline MoCA cognitive screening scores and global cognition MMSE scores collected around the time of the MEG–PET visit.
  2. MoCA, Montreal Cognitive Assessment; MMSE, mini-mental state examination.
Back to article page